Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
Question
Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
Direct answer
Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment. — bullish pressure on BHVN.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-28
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim”, revision 1, evidence through 2026-08-28. https://marketontology.com/catalysts/2026-08-28/biohaven-signs-795m-licensing-deal-with-sk-biopharm-for-opakalim-f5336e
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| BHVN | ▲Bull | 1–5 days | Catalyst Driven | 65 |
| XBI | ▲Bull | 1–4 weeks | Catalyst Driven | 64 |
Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment. — bullish pressure on BHVN.
Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
- SummaryBiohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
- BHVNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- BHVN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- BHVN price vs. pre-event level
- BHVN volume vs. 20-day average
Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment. — bullish pressure on XBI.
Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
- SummaryBiohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
- XBIDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- XBI closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XBI price vs. pre-event level
- XBI volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XBI | Bullishdisagreed | 162.38 2026-08-28 | +0.07% | +0.88% | -3.55% |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesXBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-06Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per ShareSYRE XBI
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17XBI-0.39%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.